SMTL ID : 6ugy.1

Crystal structure of the Fc fragment of anti-TNFa antibody infliximab (Remicade) in a primative orthorhombic crystal form, Lot C

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.10 Å

Oligo State

homo-dimer

Ligands

2 x NAG- NAG- BMA- MAN- NAG- GAL- MAN- FUC: beta-D-galactopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose

NAG-NAG-BMA-MAN-NAG-GAL-MAN-FUC.1: 13 residues within 4Å: Chain A: F.49, F.51, P.52, P.53, K.54, E.66, T.68, V.72, D.73, Q.103, N.105, T.107, R.109 7 PLIP interactions: 7 interactions with chain A Hydrogen bonds: A:Q.103, A:F.51, A:K.54, A:E.66, A:E.66, A:T.68 Water bridges: A:D.57, A:E.66 NAG-NAG-BMA-MAN-NAG-GAL-MAN-FUC.6: 13 residues within 4Å: Chain B: F.49, F.51, P.52, P.53, K.54, E.66, T.68, V.72, D.73, Q.103, N.105, T.107, R.109 7 PLIP interactions: 7 interactions with chain B Hydrogen bonds: B:Q.103, B:F.51, B:K.54, B:E.66, B:E.66, B:E.66 Water bridges: B:D.57, B:E.66

6 x ZN: ZINC ION(Non-covalent)

ZN.2: 4 residues within 4Å: Chain A: H.118, L.122, H.243 Ligands: ACT.5 4 PLIP interactions: 2 interactions with chain A, 1 Ligand-Water interactions, 1 Ligand-Ligand interactions Metal complexes: A:H.118, A:H.243, H2O.2, ACT.5 ZN.3: 1 residues within 4Å: Chain A: H.93 3 PLIP interactions: 1 interactions with chain A, 2 Ligand-Water interactions Metal complexes: A:H.93, H2O.1, H2O.5 ZN.4: 1 residues within 4Å: Chain A: E.126 3 PLIP interactions: 2 interactions with chain A, 1 Ligand-Water interactions Metal complexes: A:E.126, A:E.126, H2O.3 ZN.7: 4 residues within 4Å: Chain B: H.118, L.122, H.243 Ligands: ACT.10 4 PLIP interactions: 2 interactions with chain B, 1 Ligand-Water interactions, 1 Ligand-Ligand interactions Metal complexes: B:H.118, B:H.243, H2O.8, ACT.10 ZN.8: 1 residues within 4Å: Chain B: H.93 3 PLIP interactions: 1 interactions with chain B, 2 Ligand-Water interactions Metal complexes: B:H.93, H2O.7, H2O.11 ZN.9: 1 residues within 4Å: Chain B: E.126 3 PLIP interactions: 2 interactions with chain B, 1 Ligand-Water interactions Metal complexes: B:E.126, B:E.126, H2O.8

2 x ACT: ACETATE ION(Non-functional Binders)

ACT.5: 5 residues within 4Å: Chain A: H.118, Q.119, L.122, H.243 Ligands: ZN.2 3 PLIP interactions: 3 interactions with chain A Hydrophobic interactions: A:Q.119 Salt bridges: A:H.118, A:H.243 ACT.10: 5 residues within 4Å: Chain B: H.118, Q.119, L.122, H.243 Ligands: ZN.7 3 PLIP interactions: 3 interactions with chain B Hydrophobic interactions: B:Q.119 Salt bridges: B:H.118, B:H.243

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Lerch, T.F. et al., Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar. BioDrugs (2020)

Release Date

2019-11-13

Peptides

Remicade Fc: AB

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
A

Remicade Fc

Related Entries With Identical Sequence